Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗

Today 16:27 EST

Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

Topics Intellectual Property Lawsuit

Today 15:05 EST

From The Schall Law Firm

Via Business Wire

FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin ↗

Today 4:30 EST

Via Chartmill

Dow Futures Push Higher After Breaking 50,000: Why OPGN, ACHR, LI, HIMS, CING Are Trending Today ↗

February 08, 2026

HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗

Topics Stocks

February 05, 2026

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

Today 14:50 EST

Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered.

Topics Intellectual Property

Which stocks are most active on Monday? ↗

Today 14:00 EST

Via Chartmill

Why Novo Nordisk Stock Just Popped ↗

Today 12:59 EST

Everyone's ganging up on Hims & Hers stock this week.

Topics Intellectual Property Lawsuit

Which stocks are experiencing notable movement on Monday? ↗

Today 12:30 EST

Via Chartmill

Why Hims & Hers Stock Just Got Destroyed ↗

Today 12:02 EST

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 23.6% in the morning session after the company stopped offering its copycat version of Novo Nordisk's popular weight-loss drug, Wegovy,...

Topics Lawsuit

Why Hims & Hers Health (HIMS) Stock Is Nosediving

Today 11:55 EST

Via StockStory

Topics Intellectual Property Lawsuit

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

Today 11:35 EST

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

Topics Intellectual Property Lawsuit

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗

Today 11:21 EST

Novo Nordisk just did Eli Lilly stock a huge favor.

Topics Lawsuit

Why Eli Lilly Stock Just Popped ↗

Today 11:05 EST

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

Topics Lawsuit

The market is filled with gapping stocks in Monday's session. ↗

Today 10:30 EST

Via Chartmill

Today 10:19 EST

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently...

Topics Earnings Intellectual Property

The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value

Today 9:36 EST

Via Finterra

Topics Earnings Economy Intellectual Property

Monday's pre-market session: top gainers and losers ↗

Today 8:30 EST

Via Chartmill

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗

Today 7:36 EST

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗

Topics Intellectual Property Lawsuit

Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗

Today 2:36 EST

Via Chartmill

Topics Artificial Intelligence Stocks

February 08, 2026

Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.

A Billion-Dollar Kickoff: Super Bowl LX Prediction Markets Hit Record $1B in Trading Volume

Topics Intellectual Property Law Enforcement

February 08, 2026

As the Seattle Seahawks and New England Patriots prepare to take the field for Super Bowl LX at Levi’s Stadium, the real action is happening on digital ledger boards and order books. In a historic...

Via PredictStreet

Topics Derivatives

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗

February 06, 2026

The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs.

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral...

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

February 06, 2026

The drugmaker is facing pricing pressures on its weight loss medications.

Topics Economy Intellectual Property Law Enforcement

Why Shares of Novo Nordisk Stock Collapsed This Week ↗

February 06, 2026

Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗

February 05, 2026

The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs.

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗

Topics Fraud Law Enforcement

February 05, 2026

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...